Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 99; pp. 4 - 10
• Main Authors: Katsuya, Yuki, Horinouchi, Hidehito, Asao, Tetsuhiko, Kitahara, Shinsuke, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Watanabe, Shun-ichi, Tsuta, Koji, Ohe, Yuichiro
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.09.2016
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Biomarkers, Tumor; Chemotherapy; Combined Modality Therapy; Female; Gene Expression; Hematology, Oncology and Palliative Medicine; Humans; Immunogenicity; Immunohistochemistry; Male; Middle Aged; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - genetics; Neoplasms, Glandular and Epithelial - metabolism; Neoplasms, Glandular and Epithelial - mortality; PD-1; PD-L1; Prognosis; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - metabolism; Pulmonary/Respiratory; Thymic carcinoma; Thymoma; Thymus Neoplasms - drug therapy; Thymus Neoplasms - genetics; Thymus Neoplasms - metabolism; Thymus Neoplasms - mortality; Treatment Outcome; thymic carcinoma; TET; PD-L1; TM; thymoma; PD-1; chemotherapy; thymic epithelial tumor; immunogenicity; TC; Chemotherapy; Thymoma; Immunogenicity; Thymic carcinoma
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2016.05.007

Highlights • PD-L1 was positive in 67% of thymoma (TM) and 41% of thymic carcinoma (TC). • Changes in PD-L1 expression were evaluated in TM/TCs by the antibody (E1L3N). • Chemotherapy induced the expression of PD-L1 and PD-1 in TMs. • Immune check point therapies were warranted in TM/TCs.